TY - JOUR
T1 - Localised prostate cancer in elderly men aged 80–89 years, findings from a population-based registry
AU - Vatandoust, Sina
AU - Kichenadasse, Ganessan
AU - O'Callaghan, Michael
AU - Vincent, Andrew D.
AU - Kopsaftis, Tina
AU - Walsh, Scott
AU - Borg, Martin
AU - Karapetis, Christos S.
AU - Moretti, Kim
PY - 2018/5
Y1 - 2018/5
N2 - Objectives: To investigate the rate of prostate cancer-specific mortality (PCSM) and disease characteristics in patients diagnosed with localised prostate cancer at age 80–89 years in comparison with men diagnosed at age 70–79 years. Patients and Methods: This is a retrospective study of data from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC). Included were men diagnosed between 2005 and 2014, aged ≥70 years with no evidence of metastatic disease at presentation. Propensity score matching and competing risk Fine and Grey regression were used to assess the chance of treatment (curative vs non-curative) and treatment effect on PCSM. Results: Of the 1 951 eligible patients, 1 428 (76%) were aged 70–79 years and 460 (24%) were aged 80–89 years at diagnosis, with a median (interquartile range) age of 74 (72–76) and 83 (81–85) years, respectively. The 80–89 years group had higher Gleason scores and Prostate Specific Antigen (PSA) values (all P < 0.001) in comparison with the younger group. The 80–89 years group were less likely to be treated with curative treatment (odds ratio 0.12, 95% confidence interval 0.09–0.16; P < 0.001). The proportion of deaths attributable to prostate cancer was similar in both groups: 73 of 263 deaths (28%) in the 80–89 years group vs 97 of 310 deaths (31%) in the 70–79 years group. The risk of PCSM in individuals treated with curative intent was reduced in both groups. Conclusions: The proportion of prostate cancer deaths was similar in both groups. These findings support carefully selected individualised management of elderly patients diagnosed with localised prostate cancer.
AB - Objectives: To investigate the rate of prostate cancer-specific mortality (PCSM) and disease characteristics in patients diagnosed with localised prostate cancer at age 80–89 years in comparison with men diagnosed at age 70–79 years. Patients and Methods: This is a retrospective study of data from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC). Included were men diagnosed between 2005 and 2014, aged ≥70 years with no evidence of metastatic disease at presentation. Propensity score matching and competing risk Fine and Grey regression were used to assess the chance of treatment (curative vs non-curative) and treatment effect on PCSM. Results: Of the 1 951 eligible patients, 1 428 (76%) were aged 70–79 years and 460 (24%) were aged 80–89 years at diagnosis, with a median (interquartile range) age of 74 (72–76) and 83 (81–85) years, respectively. The 80–89 years group had higher Gleason scores and Prostate Specific Antigen (PSA) values (all P < 0.001) in comparison with the younger group. The 80–89 years group were less likely to be treated with curative treatment (odds ratio 0.12, 95% confidence interval 0.09–0.16; P < 0.001). The proportion of deaths attributable to prostate cancer was similar in both groups: 73 of 263 deaths (28%) in the 80–89 years group vs 97 of 310 deaths (31%) in the 70–79 years group. The risk of PCSM in individuals treated with curative intent was reduced in both groups. Conclusions: The proportion of prostate cancer deaths was similar in both groups. These findings support carefully selected individualised management of elderly patients diagnosed with localised prostate cancer.
KW - aged
KW - aged ≥80 years
KW - disease management
KW - localised prostate cancer
KW - prostate neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85048007624&partnerID=8YFLogxK
U2 - 10.1111/bju.14228
DO - 10.1111/bju.14228
M3 - Article
C2 - 29603585
AN - SCOPUS:85048007624
VL - 121
SP - 48
EP - 54
JO - British Journal of Urology International
JF - British Journal of Urology International
SN - 1464-4096
IS - S3
ER -